Skip to main navigation Skip to search Skip to main content

Differentiating Separate Primary Lung Adenocarcinomas From Intrapulmonary Metastases With Emphasis on Pathological and Molecular Considerations: Recommendations From the International Association for the Study of Lung Cancer Pathology Committee

  • Teh-Ying Chou*
  • , Sanja Dacic
  • , Ignacio Wistuba
  • , Mary Beth Beasley
  • , Sabina Berezowska
  • , Yeun-Chung Chang
  • , Jin-Haeng Chung
  • , Casey Connolly
  • , Yuchen Han
  • , Fred R. Hirsch
  • , David M. Hwang
  • , Andrew Janowczyk
  • , Philippe Joubert
  • , Keith M. Kerr
  • , Dongmei Lin
  • , Yuko Minami
  • , Mari Mino-Kenudson
  • , Andrew G. Nicholson
  • , Mauro Papotti
  • , Natasha Rekhtman
  • Anja C. Roden, J. H. von der Thüsen, William Travis, Ming-Sound Tsao, Yasushi Yatabe, Yi-Chen Yeh, Lukas Bubendorf, Wei-Chin Chang, Valeria Denninghoff, Fabio Rocha Fernandes Tavora, Takuo Hayashi, Paul Hofman, Deepali Jain, Tae-Jung Kim, Sylvie Lantuejoul, John le Quesne, Fernando Lopez-Rios, Daisuke Matsubara, Masayuki Noguchi, Teodora Radonic, Anjali Saqi, Kurt Schalper, Hyo Sup Shim, Lynette Sholl, Annikka Weissferdt, IASLC Pathology Committee
*Corresponding author for this work
  • Taipei Medical University
  • Yale University
  • University of Texas MD Anderson Cancer Center
  • Icahn School of Medicine at Mount Sinai
  • University of Lausanne
  • National Taiwan University
  • Seoul National University
  • International Association for the Study of Lung Cancer
  • Shanghai Jiao Tong University
  • Mount Sinai Hospital Medical Center
  • University of Toronto
  • Emory University
  • Université Laval
  • University of Aberdeen
  • Peking University
  • National Hospital Organization Ibarakihigashi National Hospital
  • Massachusetts General Hospital
  • Royal Brompton and Harefield NHS Foundation Trust
  • University of Turin
  • Memorial Sloan-Kettering Cancer Center
  • Mayo Clinic Rochester, MN
  • Erasmus University Rotterdam
  • University Health Network
  • National Cancer Center Japan
  • National Yang Ming Chiao Tung University
  • University of Basel
  • Consejo Nacional de Investigaciones Científicas y Técnicas
  • Universidade Federal do Ceará
  • Juntendo University
  • CHU de Nice
  • All India Institute of Medical Sciences, New Delhi
  • The Catholic University of Korea
  • Université Grenoble Alpes
  • University of Glasgow
  • Hospital Universitario 12 de Octubre
  • University of Tsukuba
  • Narita-Tomisato Tokushukai Hospital
  • Amsterdam UMC - University of Amsterdam
  • Columbia University
  • Yonsei University
  • Brigham and Women’s Hospital
  • Royal Prince Alfred Hospital

Research output: Contribution to journalArticleAcademicpeer-review

22 Downloads (Pure)

Abstract

Introduction: With the implementation of low-dose computed tomography screening, multiple pulmonary tumor nodules are diagnosed with increasing frequency and the selection of surgical treatments versus systemic therapies has become challenging on a daily basis in clinical practice. In the presence of multiple carcinomas, especially adenocarcinomas, pathologically determined to be of pulmonary origin, the distinction between separate primary lung carcinomas (SPLCs) and intrapulmonary metastases (IPMs) is important for staging, management, and prognostication. Methods: We systemically reviewed various means that aid in the differentiation between SPLCs and IPMs explored by histopathologic evaluation and molecular profiling, the latter includes DNA microsatellite analysis, array comparative genomic hybridization, TP53 and oncogenic driver mutation testing and, more recently, with promising effectiveness, next-generation sequencing comprising small- or large-scale multi-gene panels. Results: Comprehensive histologic evaluation may suffice to differentiate between SPLCs and IPMs. Nevertheless, molecular profiling using larger-scale next-generation sequencing typically provides superior discriminatory power, allowing for more accurate classification. On the basis of the literature review and expert opinions, we proposed a combined four-step histologic and molecular classification algorithm for addressing multiple pulmonary tumor nodules of adenocarcinoma histology that encourages a multidisciplinary approach. It is also noteworthy that new technologies combining machine learning and digital pathology may develop into valuable diagnostic tools for distinguishing SPLCs from IPMs in the future. Conclusions: Although histopathologic evaluation is often adequate to differentiate SPLCs from IPMs, molecular profiling should be performed when possible, especially in cases with tumors exhibiting similar morphology. This manuscript summarized the previous efforts in resolving the current challenges and highlighted the recent progress in the differentiation methods and algorithms used in categorizing multiple lung adenocarcinomas into SPLCs or IPMs, which are becoming more and more critical in precision lung cancer management.
Original languageEnglish
JournalJournal of thoracic oncology
DOIs
Publication statusE-pub ahead of print - 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Differentiating Separate Primary Lung Adenocarcinomas From Intrapulmonary Metastases With Emphasis on Pathological and Molecular Considerations: Recommendations From the International Association for the Study of Lung Cancer Pathology Committee'. Together they form a unique fingerprint.

Cite this